Get started
Author

Michelle M. Ponder

Observed names: M.M. Ponder, Michelle M Ponder, Michelle Ponder, Ponder, Michelle
OpenAlex ID: A5087478154
Phoma Infections: Classification, Potential Food Sources, and Their Clinical Impact
2018 · Ashely Bennett, Michelle Ponder, et al. · Microorganisms · 67
PDF
Increased inflammatory low-density neutrophils in severe obesity and effect of bariatric surgery: Results from case-control and prospective cohort studies
2022 · Maria Dulfary Sanchez-Pino, William S. Richardson, et al. · EBioMedicine · 44
PDF
Multicenter validation of an RNA-based assay to predict anti-PD-1 disease control in patients with recurrent or metastatic head and neck squamous cell carcinoma: the PREDAPT study
2024 · Kevin C Flanagan, Jon Earls, et al. · Journal for ImmunoTherapy of Cancer · 9
PDF
Analytical performance of OncoPrism-HNSCC, an RNA-based assay to inform immune checkpoint inhibitor treatment decisions for recurrent/metastatic head and neck squamous cell carcinoma
2025 · Jeffrey Hiken, Jon Earls, et al. · BMC Cancer · 2
PDF
Multicenter validation of an assay to predict anti-PD-1 disease control in patients with recurrent or metastatic Head and Neck Squamous Cell Carcinoma: The PREDAPT Study
2024 · Kevin C. Flanagan, Jon Earls, et al. · medRxiv · 1
PDF
Validation of a tissue-based predictive RNA test for immunotherapy benefit in NSCLC: the PREDAPT study
2026 · Kevin C. Flanagan, Jon Earls, et al. · npj Precision Oncology
PDF
Predicting Anti-PD-1 Benefit in RM-HNSCC Patients with PD-L1 CPS 1-19: A Readout From The Multi-Center PREDAPT Trial
2026 · K. Price, K. Flanagan, et al. · International Journal of Radiation Oncology*Biology*Physics
Analytical performance of OncoPrism-HNSCC, an RNA-based assay to inform immune checkpoint inhibitor treatment decisions for recurrent/metastatic head and neck squamous cell carcinoma
2024 · Jeffrey Hiken, Jon Earls, et al. · Research Square
Works count: 13
Citation count: 123
H-index: 3
I10-index: 2
Year
Topic
Type